NEW YORK (GenomeWeb News) – Rosetta Genomics today said it has received full payment from Sanra Laboratories to settle a dispute over Sanra's purchase of Parkway Clinical Laboratories from Rosetta in 2009.

Sanra paid Rosetta $625,000 as part of the settlement announced last month between the firms. Under the terms of the agreement, Sanra agreed to pay Rosetta $625,000 on top of all other payments it has paid Rosetta "for total consideration of all their obligations." Sanra previously paid Rosetta $10,000 up front.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.